{"title":"Molecular subtyping in urothelial carcinoma treatment","authors":"Xiaowen Wu, Xinan Sheng","doi":"10.1016/j.ccell.2024.11.001","DOIUrl":null,"url":null,"abstract":"The heterogeneity of urothelial carcinoma (UC) and variable treatment responses poses significant clinical challenges. In this issue of <em>Cancer Cell</em>, Hamidi et al. conducted a multi-omics analysis of 2,803 UC patients from four clinical trials with anti-PD-L1, revealing four transcriptional subtypes. This approach could help tailor therapies for UC.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"14 1","pages":""},"PeriodicalIF":48.8000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2024.11.001","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The heterogeneity of urothelial carcinoma (UC) and variable treatment responses poses significant clinical challenges. In this issue of Cancer Cell, Hamidi et al. conducted a multi-omics analysis of 2,803 UC patients from four clinical trials with anti-PD-L1, revealing four transcriptional subtypes. This approach could help tailor therapies for UC.
期刊介绍:
Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows:
Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers.
Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice.
Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers.
Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies.
Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.